key: cord-0752284-h41vu6vu
authors: Chung, Christine J.; Nazif, Tamim M.; Wolbinski, Mariusz; Hakemi, Emad; Lebehn, Mark; Brandwein, Russell; Rezende, Carolina Pinheiro; Doolittle, James; Rabbani, Leroy; Uriel, Nir; Schwartz, Allan; Biviano, Angelo; Wan, Elaine; Hathaway, Lisa; Hahn, Rebecca; Khalique, Omar; Hamid, Nadira; Ng, Vivian; Patel, Amisha; Vahl, Torsten; Kirtane, Ajay; Bapat, Vinayak; George, Isaac; Leon, Martin B.; Kodali, Susheel K.
title: The Restructuring of Structural Heart Disease Practice During The Covid-19 Pandemic
date: 2020-04-09
journal: J Am Coll Cardiol
DOI: 10.1016/j.jacc.2020.04.009
sha: e0af411945659747e531e8f13a76a838434e9bd1
doc_id: 752284
cord_uid: h41vu6vu

Abstract Patients with structural heart disease (SHD) are at increased risk of adverse outcomes from the coronavirus disease 19 (COVID-19) due to advanced age and comorbidity. In the midst of a global pandemic of a novel infectious disease, reality-based considerations comprise an important starting point for formulating clinical management pathways. The aim of these “crisis-driven” recommendations is (1) to ensure appropriate and timely treatment of SHD patients, (2) to minimize the risk of COVID-19 exposure to patients and healthcare workers, and (3) to limit resource utilization under conditions of constraint. While the degree of disruption to usual practice will vary across the United States and elsewhere, we hope that early experiences from a Heart Team operating in the current global epicenter of COVID-19 may prove useful for others adapting their practice in advance of local surges of COVID-19.

Patients with underlying cardiovascular disease (CVD) are at higher risk of both contracting the coronavirus disease 2019 (COVID- 19) and of worse outcomes after infection. (1, 2) Cardiac complications of COVID-19 include myopericarditis, malignant arrhythmias, and biventricular heart failure. (3) In the largest case series to date of over 44,000 COVID-19 patients from China, the case fatality rate was significantly higher in those with preexisting CVD (10.5% vs 2.3%).(4) Patients with severe cases of COVID-19 frequently experience acute myocardial injury, as evidenced by elevated troponin levels, which is strongly associated with clinical deterioration(5) and increased mortality. (6) Of patients with myocardial injury, prognosis is particularly poor for those with a prior history of CVD. (7) Across nations, studies have also consistently demonstrated significantly higher case fatality rates in older persons (8) (9) (10) (11) (12) , which may reflect an increased prevalence of comorbid conditions, as well as age-related declines in T-cell and B-cell function. (13) While the current literature does not yet include specific descriptions of the impact of COVID-19 in patients with structural heart disease (SHD), it is reasonable to extrapolate that these patients are high risk for adverse outcomes based on their advanced age and numerous comorbidities. In the absence of analytic outcomes data to guide evidence-based decisionmaking, reality-based considerations are necessary surrogates in formulating clinical pathways in the context of a global pandemic. The focus of these "crisis-driven" recommendations is (1) to ensure appropriate, sensitive, and timely treatment of SHD patients, (2) to minimize the risk of COVID-19 exposure to patients and healthcare workers, and (3) to limit resource utilization under conditions of constraint. We draw heavily on our early experiences as a high-volume Heart Team at a large academic medical center in New York City, currently the global epicenter of COVID-19. While the degree of disruption to usual practice will vary across regions in the United States and elsewhere owing to differences in population density, rates of community spread, time to peak disease burden, and resource availability, we hope that early experiences from our center may prove useful for others adapting their practice in preparation for local COVID-19 surges.

With widespread community transmission of COVID-19 throughout the United States, the overarching goal is to minimize the risk of COVID-19 exposure and to preserve limited resources such as anesthesia care, ventilators, intensive care unit (ICU) beds, and personal protective equipment (PPE). By early March 2020, COVID-19 infection rates were rapidly increasing in NY, and in accordance with guidelines issued by our hospital administration, all elective procedures and surgeries were cancelled and non-urgent outpatient visits were discouraged. Patients scheduled for Valve Clinic visits over the next two months were contacted and offered two options: either keeping the original appointment but converting to a telemedicine encounter, or postponing until a future date when it becomes safer to have an in-person visit.

There was clearly some self-selection bias, such that patients with greater symptoms generally agreed to an earlier telemedicine visit while less symptomatic, more stable patients tended to prefer a delayed in-person visit.

Conducting a comprehensive new patient evaluation for SHD remotely is labor-intensive and presents challenges for elderly patients who may lack sophisticated knowledge of technology and access to a device with a streaming video camera. Family members or friends who would otherwise assist with setting up devices and navigating unfamiliar applications are now isolated from elderly patients and can no longer be relied upon to provide on-site technical support. An integrated team is therefore necessary to facilitate telemedicine, and multiple interactions with the patient are needed prior to the scheduled visit with the physician to streamline the actual encounter. Office staff must obtain images of the most recent prior echocardiogram and guide patients through the process of downloading and registering the telemedicine application. The preferred application at our institution is MyChart, since it provides a secure HIPAA-compliant interface that is compatible with Epic, an electronic medical record platform. A physician assistant obtains a detailed medical history, reconciles medications, and sets expectations so patients understand in advance that all elective procedures are currently postponed. An hour prior to the telemedicine visit, a medical assistant calls to ensure the patient is logged on to the application in a quiet, appropriate space. In instances where an unstable internet connection or other technical limitations prevent a patient from successfully using MyChart, we have used FaceTime and web conferencing applications such as Zoom to facilitate a video encounter. A video encounter offers distinct advantages over a phone call alone, as it enables subjective assessments of frailty, dyspnea and a limited evaluation of volume status. Albeit imperfect, a web camera pointed at a patient's legs can convey severity of peripheral edema. When all else fails, a phone call substituted for a video visit will still allow some degree of patient assessment and be acknowledged for coverage by Medicare. Similarly, there is coverage of subsequent, brief patient-initiated telephone or online communications with a healthcare provider, termed "virtual check-ins" (14) .

The ability to deliver such remote services was facilitated by the decision from the Centers for Medicare & Medicaid Services (CMS), effective March 6, 2020, to temporarily expand Medicare coverage for telemedicine using a wider range of communication tools, including smartphones, enabling beneficiaries to receive many health services without incurring the risks of leaving their homes. The ability to convert nearly any evaluation by the Heart Team to a telemedicine encounter was further enhanced by a temporary CMS waiver of state-specific licensing requirements allowing physicians to see patients residing in neighboring states. (14) In addition, the Health and Human Services Office for Civil Rights waived penalties for providers acting in good faith who perform telemedicine visits using broadly available technologies like FaceTime that are not HIPAA-compliant.

As the vast majority of patient-physician interactions during the COVID-19 pandemic will transition to a remote interface, clear communication is critical to ensure that patients continue to receive high-quality cardiac care. Patients must be given specific instructions on how to self-monitor symptoms at home and when to call the clinic or consider an emergency department evaluation. Expectations should be conveyed regarding the frequency of follow-up with the medical team and the anticipated timeframe of eventual structural intervention. Given the fluidity and changing dynamics of the current crisis, cases may need to be postponed multiple times and for several months. Frequent, transparent communication will give patients confidence that their care is not being neglected. In the event that Heart Team members are re-assigned to new roles staffing COVID-19 units, or they themselves become sick, contingency plans for coverage of outpatient responsibilities should be assured.

Any intervention that is unlikely to directly impact clinical care or outcomes over the next two to three months should be considered elective and be postponed. This includes procedures such as left atrial appendage occlusion and closure of atrial septal defects and patent foramen ovales, which are unlikely to impact short term morbidity and mortality. Similarly, interventions for tricuspid regurgitation, which are currently possible only as part of clinical trial investigations, should generally be deferred unless local COVID-19 burden is low and resources are not constrained. The rationale for deferring elective procedures should be discussed with patients and documented in the medical record.

In contrast, for patients with an imminent risk of mortality, threat of irreversible clinical consequences (e.g. permanent organ system dysfunction), or likelihood of rapidly worsening symptoms that could provoke hospitalization, an intervention can be deemed emergent or urgent based on the acuity and severity of risk ( Figure 1 ). Most emergent cases will be inpatients in whom worsening hemodynamic compromise and impending multi-organ failure require an intervention within hours or one to two days. Examples would be cases of severe aortic stenosis (AS) with cardiogenic shock requiring inotropes or vasopressors and severe mitral regurgitation (MR) with refractory heart failure requiring an intra-aortic balloon pump. Examples of urgent cases of the highest risk strata (Tier 1), would include inpatients that cannot be safely discharged without a procedure, such as a patient with AS admitted with refractory heart failure, or an outpatient at high risk for decompensation in the next two weeks, such as a patient with AS with recurrent syncope. These Tier 1 patients should be treated during the hospitalization or within one week, whereas urgent patients of lower risk (Tier 2) and elective cases (Tier 3), can be triaged for treatment over the subsequent months as outlined below.

Outpatients can be triaged based on a previous Heart Valve Clinic visit or telemedicine At our center, all procedures which were originally scheduled for the next two months were cancelled; the affected patients were subsequently categorized and re-prioritized according to the above criteria. Given the limitations of telemedicine, every new outpatient currently receives a follow-up call within one to two weeks of the initial encounter to ensure they are stable prior to scheduling future check-ins according to their tier of risk. Tier 2 patients receive weekly or biweekly check-in calls whereas Tier 3 patients receive check-in calls every one to two months. Tier 3 patients should be followed according to existing guidelines, when possible, but priority should still be given to minimizing both risk of exposure to COVID-19 and resource consumption. For instance, serial echocardiography in patients with asymptomatic severe AS can be performed less frequently than every 6-12 months, if the patient remains asymptomatic.

Maintenance of close communication with patients is critical to ensure ongoing delivery of optimal cardiac care. A report from one Hong Kong hospital found a significantly longer time from symptom onset to first medical contact in patients presenting with ST-segment elevation myocardial infarction (STEMI) from late January to mid-February 2020, possibly reflecting patients' fear of exposure to COVID-19 in the hospital. (15) It is imperative that Heart Teams educate patients and referring physicians, and provide clear guidance on when to request phone consultations or urgent in-person evaluations to minimize avoidable morbidity and mortality due to delayed care. Clearly, this is a dynamic situation and patients with clinical deterioration should be re-categorized and re-prioritized, as appropriate.

As COVID-19 hospital admissions continue to increase, the demand for access to medical treatment is anticipated to outstrip existing resources across the United States. In the context of a pandemic, it is ethically permissible to limit access to procedures requiring disproportionate resource utilization and hindering the ability to mount an effective response to the pandemic. (16) To ensure fair and consistent application of limited access, prospective guidelines for fair allocation of resources should be developed based upon maximizing the number of lives saved (utilitarianism), rewarding instrumental value (social usefulness), and prioritizing those who are worst off. (17, 18) In the context of the current COVID-19 pandemic, members of the Heart Team must determine which patients are unlikely to derive sufficient benefit from an urgent procedure to warrant diversion of scarce resources, including anesthesia services, ICU beds, ventilators and PPE. We propose that patients who are less likely to achieve meaningful improvement in health status, including those with advanced age, especially with associated frailty or dementia, should be deferred for structural heart procedures. Additionally, elderly patients with severe hemodynamic compromise and threatened multi-organ failure should generally not undergo salvage procedures. In making these challenging decisions, programs should weigh the patient's severity of presentation (as indicated by his or her Tier), the expected benefit, the likelihood of an uncomplicated procedure, and the degree of resource limitation (Central Illustration).

Similarly, surgical procedures, including valve repair or replacement, should be avoided whenever possible. In general, low-risk patients with severe AS who would normally be considered good candidates for surgery, should instead be considered for TAVR, provided the anatomy is reasonable, especially in regions where hospitals are facing imminent surges in ICU occupancy.

When weighing whether and when to move forward with even an urgent structural heart intervention, preference should be given to patients with straightforward anatomy whose procedures can be performed with low or reasonable risk of complications and minimal resource utilization. For example, in TAVR candidates, this would include cases that can be safely performed under conscious sedation, with a low risk of vascular access complications or need for a permanent pacemaker, and a high probability of same-day or next-day hospital discharge to home. Mitraclip cases should generally be avoided, except in emergent or Tier 1 cases, due to the increased risks to the procedure team associated with intubation and transesophageal echocardiography. Balloon aortic valvuloplasty (BAV) can be considered as a temporizing or "bridging" procedure in select patients with severe AS, particularly those with unfavorable iliofemoral arterial access, suboptimal aortic valvular complex anatomy or impaired renal function hindering the ability to obtain a TAVR CTA. However, even careful planning cannot guarantee an absence of complications, particularly in elderly and frail patients. Thus, higher-risk co-morbid patients being considered for a BAV because they are not good candidates for a TAVR should also be considered for palliative care.

Once a decision is made to move forward with a structural procedure, pre-procedural testing should be streamlined to minimize the number of interactions with healthcare personnel.

Echocardiograms performed within the past six months are generally sufficient and coronary angiograms (if necessary) should be performed at the time of the intervention. The only preprocedural testing which is essential for TAVR is computed tomographic angiography (CTA) performed within the past few years, as it enables assessment of vascular access, aortic valve anatomy and overall procedural risk, which in turn guides the decision to move forward with the procedure. When possible, pre-procedural testing should be performed in outpatient settings where there is a lower risk of patient exposure to COVID-19.

Guiding principles for structural interventions are similar to those that have been recently proposed for the treatment of patients with acute coronary syndromes. (19) All patients should undergo clinical screening and expedited testing for COVID-19. To minimize the risk of exposure to COVID-19 and to conserve PPE, the treatment team should be limited to essential personnel and should not include trainees. We agree with recommendations from the ACC Interventional Council and SCAI that those who scrub for procedures should don PPE suitable for airborne precautions, including an N95 respirator and a face shield, given the risk of emergent intubation and need for cardiopulmonary resuscitation (20) . Patients with unstable, deteriorating respiratory conditions should be intubated prior to transfer to minimize the risk of intubation in the CCL. Use of high-flow nasal cannula and non-invasive positive pressure ventilation should be avoided, as they are associated with increased generation of infectious aerosols.

TAVR should be performed with a modified minimalist approach including use of conscious sedation, avoidance of transesophageal echocardiography, and specific plans to minimize the length of stay in the hospital (21, 22) . Every effort should be undertaken to ensure a safe, expedited recovery and discharge to home (Figure 4) .

A 61-year-old woman with multiple comorbidities and recent hospitalization for decompensated heart failure was referred for urgent evaluation of symptomatic severe AS with a Sievers Type 1 bicuspid aortic valve and preserved left ventricular function. She had a history of Type 2 diabetes mellitus, coronary artery disease recently treated with percutaneous coronary intervention, and chronic obstructive pulmonary disease. She had presented to a local hospital with acute pulmonary edema requiring emergent intubation and aggressive diuresis. She was discharged within 2 days, but soon afterward, developed recurrent syncopal episodes.

Importantly, testing for COVID-19 was negative.

Given her progressive symptoms and failure of medical management, there was consensus that she qualified as a Tier 1 candidate for TAVR. There was consideration of direct hospital transfer; however, due to severe constraints on ICU availability and risk of exposure to COVID-19, expedited outpatient treatment was preferred. Under normal circumstances, given her young age and bicuspid anatomy, she would have been considered for surgical valve replacement. However, her anatomy was also reasonable for TAVR, so to avoid the increased risk of COVID-19 exposure with inpatient admission, as well as utilization of an ICU bed, the Heart Valve Team agreed to proceed with TAVR as the preferred alternative, with a plan for same-day discharge.

The patient underwent transfemoral TAVR under conscious sedation with successful implantation of a 23 mm Evolut Pro Plus valve. She developed PR-interval prolongation and a new left bundle branch block after valve deployment. Current recommendations are to monitor such patients for 24 hours, or at least overnight, with a temporary transvenous pacemaker in place (23). In anticipation of this possible scenario, however, there were preemptive discussions with electrophysiology colleagues to ensure their availability for immediate implantation of a permanent pacemaker in the CCL to avoid an ICU admission. As such, a permanent dualchamber pacemaker was implanted immediately with a plan to reassess the patient in three months and to explant her device if she is found not to require significant pacing. She was discharged home on the same day of the procedure to the care of her family, and is currently doing well without complications at one week post-procedure. Though not a typical costeffective treatment strategy, it was felt to be appropriate in the current pandemic environment, balancing the needs of the patient with the overall needs of the general population.

This case illustrates several ways in which the COVID-19 pandemic necessitates deviation from usual practice in the provision of care to patients with SHD. First, the initial decision to avoid an inpatient transfer was driven by the need for thoughtful resource allocation during a time of scarcity. Second, the decision to offer TAVR rather than surgery was heavily influenced by the need to reserve ICU capacity for critically ill COVID-19 patients and to minimize the patient's risk of nosocomial infection. Third, the decision to preemptively implant a permanent pacemaker rather than wait the usual time for monitoring arose from the aforementioned priorities. Each decision reflected an endeavor to provide optimal cardiac care in the context of a global health crisis. Regional variations in resource availability and the timing of COVID-19 surges will determine the extent to which other programs will need to limit resource utilization in the care of non-COVID-19 patients with SHD.

Once the severity of the COVID-19 pandemic begins to lessen, there will be a gradual release of strain on the healthcare system, allowing a staged return to normalcy. Though flattening of the curve should prevent some hospitals from being overwhelmed, this pandemic is likely to have a long "tail" and adjustments to usual practice will be necessary well into the foreseeable future. Until a vaccine becomes widely available, it will remain a priority to conduct outpatient services, pre-procedural testing and structural heart procedures following the general principles of social distancing and utilization of adequate PPE to minimize risk of COVID-19 transmission.

As outpatients undergo evaluation and are categorized according to the framework delineated in Figure 1 , they are maintained on a constantly evolving list reflecting the order in which cases will be performed as the healthcare system recovers. There is continual reassessment of Tier 2 cases to ensure that high-risk candidates for intervention are not worsening to the point that procedural risk becomes excessive and the opportunity to derive meaningful benefit is lost. The goal is to intervene on Tier 2 patients at the earliest reasonable time while continuing to minimize risk of exposure to COVID-19 and to exercise responsible stewardship of limited resources. Same-day or next-day discharge without ICU occupancy should be prioritized whenever possible. When this is not possible, patients should be admitted to an area with the lowest concentration of COVID-19 patients. In some instances, this may necessitate moving patients out of the hospital to an off-site facility dedicated to non-COVID-19 patients. In regions without a heavy burden of COVID-19 at the present time, it is reasonable to continue performing Tier 1 and Tier 2 cases, as long as they are not resulting in prolonged hospital stays and consuming disproportionate resources (Figure 2, Figure 5 ).

As the burden of COVID-19 on the healthcare system lightens further and increasing numbers of postponed cases are able to be performed, programs will need to find creative ways to alleviate the backlog of elective patients requiring procedures. In addition to structural cases, there will also be a backlog of coronary and endovascular cases that will compete for limited time in the catheterization laboratory. Also there will also be a backlog of elective surgical cases competing for ICU resources. In many programs, expanded treatment hours including weekend schedules will become necessary to handle increased case numbers. Given significant geographical differences in COVID-19 burden and subsequent resource restrictions, patients with the means to do so may be advised to travel to other programs in less stressed healthcare environments. An important component to maintaining strong relationships with patients and referring physicians during this period of great uncertainty will be frequent, transparent communication and a sensitivity to patient needs and preferences. In the midst of an overwhelming crisis, it is difficult to chart a path to normalcy in the future. Though it remains unclear when the current pandemic will come to an end, when it does, Heart Teams across the country must be prepared to shift gears back to what they do best. 

ACC Clinical Bulletin COVID-19 Clinical Guidance for the Cardiovascular Care Team

COVID-19) and Cardiovascular Disease

Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the Coronavirus Disease 2019 (COVID-19) Pandemic

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Potential Effects of Coronaviruses on the Cardiovascular System: A Review

Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19)

Clinical Characteristics of Coronavirus Disease 2019 in China

Similarity in Case Fatality Rates (CFR) of COVID-19/SARS-COV-2 in Italy and China

Report on the Epidemiological Features of Coronavirus Disease 2019 (COVID-19) Outbreak in the Republic of Korea from

Covid-19 in Critically Ill Patients in the Seattle Region -Case Series

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

The immunopathogenesis of sepsis in elderly patients

Medicare Telemedicine Health Care Provider Fact Sheet

Outbreak on ST-Segment-Elevation Myocardial Infarction Care in Hong Kong

Ethical considerations: care of the critically ill and injured during pandemics and disasters: CHEST consensus statement

Principles for allocation of scarce medical interventions

Fair Allocation of Scarce Medical Resources in the Time of Covid-19

Considerations for Cardiac Catheterization Laboratory Procedures During the COVID-19 Pandemic Perspectives from the Society for Cardiovascular Angiography and Interventions Emerging Leader Mentorship (SCAI ELM) Members and Graduates

Catheterization Laboratory Considerations During the Coronavirus (COVID-19) Pandemic: From ACC's Interventional Council and SCAI

Risk stratification and clinical pathways to optimize length of stay after transcatheter aortic valve replacement

The Vancouver 3M (Multidisciplinary, Multimodality, But Minimalist) Clinical Pathway Facilitates Safe Next-Day Discharge Home at Low-, Medium-, and High-Volume Transfemoral Transcatheter Aortic Valve Replacement Centers: The 3M TAVR Study